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verything that doctors and other 
health workers do involves 
communication about the 
beneﬁ  ts and harms to be expected 
from interventions—whether they are 
therapeutic, diagnostic, or prophylactic. 
As health-care professionals, we need 
to share our understanding and 
perceptions of beneﬁ  ts and harms with 
patients and their families as fully as 
we can. We also have to share them 
with other professionals. When we do 
so we have to remember that how we 
personally value particular beneﬁ  ts 
and harms may well differ from how 
another person values them.
A clinician who recommends an 
intervention does so in the belief that 
its beneﬁ  ts outweigh the harms that it 
can cause. In most consultations there 
is little time in which to explain in 
detail what these beneﬁ  ts and harms 
are, or to ﬁ  nd out what the patient 
thinks about them. Moreover, most 
clinicians are not trained or practised at 
describing and explaining beneﬁ  ts and 
harms clearly to patients, and much 
of the time they also lack important 
information about these aspects.
“Risk” Versus “Harm”
The problems begin with the word 
“risk”. Very often people use it when 
they mean “harm”, and this causes 
ambiguities and confusion. The 
widely used expression “beneﬁ  t/risk 
ratio” is meaningless—no such ratio 
exists. Before a decision is made to 
use an intervention, its beneﬁ  ts and 
harms must be weighed, ideally by the 
clinician and the patient together. 
Other advantages and disadvantages, 
such as convenience and cost, may also 
be relevant. This analysis requires use 
of the same dimensions for considering 
both beneﬁ  ts and harms. These 
dimensions have not been generally 
recognised or taught, though they seem 
obvious enough.
In this context any beneﬁ  t or harm 
has four dimensions (see sidebar). The 
clinician is expected to know or ﬁ  nd 
out about the nature and probability 
of each beneﬁ  t and harm, and how to 
maximise beneﬁ  ts and minimise harms. 
A great many clinicians do not meet 
this expectation, and often that is not 
their fault. But only patients can say 
how they regard the hoped for beneﬁ  ts 
and the possible harms, though they 
may need help to think clearly about 
them. Clinicians should identify how 
much the beneﬁ  ts matter to their 
patient—for example, are the beneﬁ  ts 
of taking a medicine or having an 
operation “worth the trouble”?—and 
whether a speciﬁ  c harm is particularly 
threatening or would be intolerable to 
that particular patient. People’s fears, 
wishes, and priorities differ greatly and 
unpredictably.
The deepening of the voice that 
occurs with long-term use of tamoxifen 
for breast cancer, and that is usually 
irreversible, is an example of a side 
effect that prescribers, manufacturers, 
and drug regulators have considered 
trivial and have largely ignored. While 
this side effect does not bother most 
women, for professional or keen 
amateur singers it is a disaster—it can 
rob them of what they enjoy most.
A patient who is offered a treatment 
with serious implications needs time 
and encouragement to think, and to 
talk to other people, before making 
a decision. Three major issues are 
important in helping patients with 
decision-making: obtaining reliable 
information about beneﬁ  ts and harms, 
effectively communicating probabilities 
to the patient, and determining what 
to do to reverse or mitigate harmful 
effects when they occur.
Explaining Uncertainties 
and Probabilities
Innumeracy is very widespread. Many 
people cannot handle percentages, and 
most are unclear about the meaning 
of “relative risk”, “absolute risk”, 
“odds ratio”, and “number needed to 
treat”, including many clinicians who 
want to tell their patients about the 
likelihood of beneﬁ  ts or harms [1]. 
Gigerenzer has shown that information 
on outcomes presented as natural 
frequencies (for example, “a one 
in ﬁ  ve chance”) is much easier to 
understand than information expressed 
in probabilities (for example, “a 20% 
chance”) [2]. The reason, he suggests, 
is that “natural frequencies result from 
natural sampling, the process by which 
humans and animals have encountered 
information about risks during most 
of their evolution” ([1], p. 48–49). 
So, to put it in its simplest form, it is 
most effective to say to a patient “this 
treatment is effective in eight patients 
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out of ten”, or “this drug causes nausea 
or vomiting in three people out of 
every ten who use it”.
Obtaining Reliable Information
The effectiveness of an intervention 
(the extent to which a treatment 
produces a beneﬁ  cial effect when 
implemented under the usual 
conditions of clinical care for a 
particular group of patients) is most 
readily estimated from controlled 
clinical trials. With the rise of evidence-
based medicine, there are now many 
more critical analyses, systematic 
reviews, and meta-analyses of the best 
evidence, as in the rapidly growing 
Cochrane Database of Systematic 
Reviews (www.cochrane.org). 
Nevertheless, there are huge gaps—we 
still lack reliable evidence about many 
important interventions. 
Even in the case of common 
conditions for which many high-quality 
trials have been published, trial reports 
have not addressed some elementary 
questions, for example, on optimal 
drug dosage and duration of treatment. 
Almost all drug effects are related to 
dose [3], but we rarely learn what the 
lowest effective dosage is in different 
circumstances, and how far it is worth 
increasing the dosage if the effect is 
insufﬁ  cient. 
Details of dose–response 
relationships are hardly ever published. 
They are usually studied early in the 
development of a drug in a relatively 
small number of volunteers, and are 
used to decide on the dosages to be 
used in the major clinical trials that will 
support the licensing application. They 
are regarded as internal working data 
of the company, which is not interested 
in publishing them. Regulatory 
agencies do not appear to ask for them 
or examine them critically. Everybody 
now habitually uses means and group 
differences to judge effectiveness, 
although individuals commonly differ 
greatly in their sensitivity to both 
beneﬁ  cial and harmful effects of drugs. 
This thoughtless reliance on means 
and group differences, which ignores 
an important dimension of evidence, 
is now embedded in “evidence-based 
practice”. Marketing departments 
prefer a “one size ﬁ  ts all” approach: it 
is hard to sell a drug whose dose may 
need to be titrated. 
Another important unanswered 
question is the variation in response 
between individuals. Because 
controlled trials compare treatments 
they usually report only group means 
and test their signiﬁ  cance. This gives 
clinicians no help in treating people 
who are more or less sensitive to the 
drug than average.
Reliable information on harms is 
for several reasons even harder to 
get [4]. Far less research is done to 
investigate them. Companies do not 
want to do more work than regulators 
require, and once they have marketed 
a drug they hesitate to pay for more 
research, especially if the results 
might be inconvenient. Independent 
public funding hardly exists. Many 
kinds of harm—often unforeseen and 
uncommon—need to be ﬁ  rst detected 
and then diligently investigated and 
analysed. And the available research 
designs yield less robust evidence 
than can be obtained for predeﬁ  ned 
therapeutic effects. Here, too, dose–
response data are almost completely 
lacking.
Thus, much of the time prescribers 
and patients are poorly informed, and 
have to rely on cautious exploration, 
common sense, and personal 
experience. Nevertheless, as Yoon 
Kong Loke has pointed out, there are 
certainly some situations at the bedside 
when it is particularly important to base 
treatment decisions on as precise an 
estimate as possible of the balance of 
beneﬁ  ts and harms [5]. An example is 
when there is a narrow margin between 
beneﬁ  t and harm, such as giving 
aspirin to a patient with a stroke who 
has a past history of gastrointestinal 
haemorrhage. Another example is 
when there are several efﬁ  cacious 
treatments with differing safety proﬁ  les, 
such as warfarin versus aspirin in a 
healthy, middle-aged patient with lone 
atrial ﬁ  brillation.
Checking Effectiveness and 
Detecting and Dealing with Harms 
Doctor and patient need to work 
together to check that the treatment is 
as effective as intended, and to detect 
possible harm promptly. Monitoring 
can be left to patients if they (or the 
family) can understand what to watch 
for and what to do if a problem arises. 
If not, or if examination or lab tests are 
necessary, then monitoring and follow-
up by a nurse or doctor will need to be 
arranged. 
Here is a checklist of points for 
clinicians—and of course also drug 
regulators—to consider. (1) When an 
adverse effect occurs, should the dose 
be reduced, or the drug changed? (2) If 
reduced, by how much? (3) Is reducing 
the dose possible and practicable with 
the available preparations? (4) How 
and over what time should the effect of 
the change be observed and assessed? 
(5) Should the patient, as well as the 
clinician, keep the records of adverse 
effect(s) and their intensity and 
timing? Such notes can help both the 
patient and current and future doctors. 
Medication experiences can remain 
relevant for life. (6) Should an adverse 
effect be reported to a local or national 
adverse drug reaction register? (If in 
doubt, the answer is yes).
Conclusion
Effective communication about harms 
and risks is an essential component 
of care, and it requires learning, 
preparation, and rehearsal. The onus 
lies with professionals to persuade and 
to teach patients to play their part in 
coming to an informed decision about 
treatments.  
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The Four Dimensions of Any 
Beneﬁ  t or Harm
1. Its nature, described by its quality, 
its intensity, and its time course (onset, 
duration, and reversibility).
2. The probability that it will occur.
3. Its importance to the person 
experiencing it.
4. How the beneﬁ  t can be maximised, or 
the harm prevented or minimised.
We still lack reliable 
evidence about many 
important interventions.
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